Cargando…
Targeting mTOR dependency in pancreatic cancer
OBJECTIVE: Pancreatic cancer is a leading cause of cancer-related death in the Western world. Current chemotherapy regimens have modest survival benefit. Thus, novel, effective therapies are required for treatment of this disease. DESIGN: Activating KRAS mutation almost always drives pancreatic tumo...
Autores principales: | Morran, Douglas C, Wu, Jianmin, Jamieson, Nigel B, Mrowinska, Agata, Kalna, Gabriela, Karim, Saadia A, Au, Amy Y M, Scarlett, Christopher J, Chang, David K, Pajak, Malgorzata Z, Oien, Karin A, McKay, Colin J, Carter, C Ross, Gillen, Gerry, Champion, Sue, Pimlott, Sally L, Anderson, Kurt I, Evans, T R Jeffry, Grimmond, Sean M, Biankin, Andrew V, Sansom, Owen J, Morton, Jennifer P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145424/ https://www.ncbi.nlm.nih.gov/pubmed/24717934 http://dx.doi.org/10.1136/gutjnl-2013-306202 |
Ejemplares similares
-
Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
por: Chou, Angela, et al.
Publicado: (2018) -
LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest
por: Morton, Jennifer P., et al.
Publicado: (2010) -
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer
por: De Santis, Maria Chiara, et al.
Publicado: (2023) -
Differences in receipt of multimodality therapy by race, insurance status, and socioeconomic disadvantage in patients with resected pancreatic cancer
por: Hao, Scarlett, et al.
Publicado: (2022) -
GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer
por: Martinelli, Paola, et al.
Publicado: (2017)